HIV-1	B-protein
envelope	I-protein
glycoproteins	I-protein
induce	O
activation	O
of	O
activated	O
protein-1	B-protein
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Dec	O
1	O
;	O
270	O
(	O
48	O
)	O
:	O
29038	O
]	O

Activation	O
of	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
is	O
a	O
primary	O
requirement	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
entry	O
,	O
efficient	O
HIV	O
replication	O
,	O
and	O
progression	O
to	O
AIDS	O
,	O
Utilizing	O
CD4	B-cell_line
positive	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
,	O
we	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV	O
,	O
gp	B-protein
160	I-protein
,	O
can	O
induce	O
activation	O
of	O
transcription	B-protein
factor	I-protein
,	I-protein
activated	I-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	B-protein
are	O
mediated	O
through	O
the	O
CD4	B-protein
molecule	I-protein
,	O
since	O
treatment	O
of	O
gp160	B-protein
with	O
soluble	O
CD4-IgG	B-protein
abrogates	O
its	O
activity	O
,	O
and	O
CD4	B-cell_line
negative	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
fail	O
to	O
be	O
stimulated	O
with	O
gp160	B-protein
.	O

Immunoprecipitation	O
of	O
the	O
gp	B-protein
160	I-protein
-induced	O
nuclear	O
extracts	O
with	O
polyclonal	B-protein
antibodies	I-protein
to	O
Fos	B-protein
and	O
Jun	B-protein
proteins	I-protein
indicates	O
that	O
AP-1	B-protein
complex	I-protein
is	O
comprised	O
of	O
members	O
of	O
these	O
family	O
of	O
proteins	O
.	O

The	O
gp160-induced	B-protein
AP-1	I-protein
complex	I-protein
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
and	O
is	O
protein	O
synthesis-independent	O
.	O

This	O
stimulation	O
can	O
also	O
be	O
abolished	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
it	O
is	O
unaffected	O
by	O
calcium	O
channel	O
blocker	O
or	O
cyclosporine	O
A	O
.	O

This	O
gp160	B-protein
treatment	O
adversely	O
affects	O
the	O
functional	O
capabilities	O
of	O
T	B-cell_type
cells	I-cell_type
:	O
pre-treatment	O
of	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
gp160	B-protein
for	O
4	O
h	O
at	O
37	O
degrees	O
C	O
inhibited	O
anti-CD3	B-protein
-induced	O
interleukin-2	B-protein
secretion	O
.	O

Effects	O
similar	O
to	O
gp160	B-protein
were	O
seen	O
with	O
anti-CD4	B-protein
mAb	I-protein
.	O

The	O
aberrant	O
activation	O
of	O
AP-1	B-protein
by	O
gp160	B-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
could	O
result	O
in	O
up-regulation	O
of	O
cytokines	B-protein
containing	O
AP-1	B-DNA
sites	I-DNA
,	O
e.g	O
.	O
interleukin-3	B-protein
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
,	O
and	O
concurrently	O
lead	O
to	O
T	B-cell_type
cell	I-cell_type
unresponsiveness	O
by	O
inhibiting	O
interleukin-2	B-protein
secretion	O
.	O

THE	NULL
JourNat	NULL
or	NULL
BioLocicaL	NULL
CHEMISTRY	NULL
©	NULL
1995	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

270	NULL
,	NULL
No	NULL
.	NULL

33	NULL
,	NULL
Issue	NULL
of	NULL
August	NULL
18	NULL
,	NULL
pp	NULL
.	NULL

19364-19369	NULL
,	NULL
1995	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
HIV-1	NULL
Envelope	NULL
Glycoproteins	NULL
Induce	NULL
Activation	NULL
of	NULL
Activated	NULL
Protein-1	NULL
in	NULL
CD4+	NULL
T	NULL
Cells*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
February	NULL
2	NULL
,	NULL
1995	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
June	NULL
2	NULL
,	NULL
1995	NULL
)	NULL
Narendra	NULL
Chirmule	NULL
?	NULL
}	NULL

,	NULL
Harris	NULL
Goonewardena	NULL
,	NULL
Sunil	NULL
Pahwag	NULL
,	NULL
Regina	NULL
Pasieka	NULL
,	NULL
Vaniambadi	NULL
S.	NULL
and	NULL
Savita	NULL
Pahwa	NULL
#	NULL
From	NULL
the	NULL
Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
North	NULL
Shore	NULL
University	NULL
Hospital	NULL
,	NULL
Cornell	NULL
University	NULL
Medical	NULL
College	NULL
,	NULL
Manhasset	NULL
,	NULL
New	NULL
York	NULL
11030	NULL
and	NULL
§	NULL
$	NULL
Advanced	NULL
BioScience	NULL
Labs	NULL
Inc.	NULL
,	NULL
Kensington	NULL
,	NULL
Maryland	NULL
20872	NULL
Activation	NULL
of	NULL
CD4	NULL
positive	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
primary	NULL
requirement	NULL
for	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
entry	NULL
,	NULL
efficient	NULL
HIV	NULL
replication	NULL
,	NULL
and	NULL
progression	NULL
to	NULL
AIDS	NULL
.	NULL

Utilizing	NULL
CD4	NULL
positive	NULL
T	NULL
cell	NULL
lines	NULL
and	NULL
purified	NULL
T	NULL
cells	NULL
from	NULL
normal	NULL
individuals	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
native	NULL
envelope	NULL
glycoproteins	NULL
of	NULL
HIV	NULL
,	NULL
gp160	NULL
,	NULL
can	NULL
induce	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
,	NULL
activated	NULL
protein-1	NULL
(	NULL
AP-1	NULL
)	NULL
.	NULL

The	NULL
stimulatory	NULL
effects	NULL
of	NULL
gp160	NULL
are	NULL
mediated	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
,	NULL
since	NULL
treatment	NULL
of	NULL
gp160	NULL
with	NULL
soluble	NULL
CD4-IgG	NULL
abrogates	NULL
its	NULL
activity	NULL
,	NULL
and	NULL
CD4	NULL
negative	NULL
T	NULL
cell	NULL
lines	NULL
fail	NULL
to	NULL
be	NULL
stimulated	NULL
with	NULL
gp160	NULL
.	NULL

Immunoprecipitation	NULL
of	NULL
the	NULL
gp160-induced	NULL
nuclear	NULL
extracts	NULL
with	NULL
polyclonal	NULL
antibodies	NULL
to	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
indicates	NULL
that	NULL
AP-1	NULL
complex	NULL
is	NULL
comprised	NULL
of	NULL
members	NULL
of	NULL
these	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

The	NULL
gp160-induced	NULL
AP-1	NULL
complex	NULL
is	NULL
dependent	NULL
upon	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
is	NULL
protein	NULL
synthesis-independent	NULL
.	NULL

This	NULL
stimulation	NULL
can	NULL
also	NULL
be	NULL
abolished	NULL
by	NULL
inhibitors	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
but	NULL
it	NULL
is	NULL
unaffected	NULL
by	NULL
calcium	NULL
channel	NULL
blocker	NULL
or	NULL
cyclosporine	NULL
A	NULL
.	NULL

This	NULL
gp160	NULL
treatment	NULL
adversely	NULL
affects	NULL
the	NULL
functional	NULL
capabilities	NULL
of	NULL
T	NULL
cells	NULL
;	NULL
pretreatment	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
with	NULL
gp160	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
inhibited	NULL
anti-CD3-induced	NULL
interleukin-2	NULL
secretion	NULL
.	NULL

Effects	NULL
similar	NULL
to	NULL
gp160	NULL
were	NULL
seen	NULL
with	NULL
anti-CD4	NULL
mAb	NULL
.	NULL

The	NULL
aberrant	NULL
activation	NULL
of	NULL
AP-1	NULL
by	NULL
gp160	NULL
in	NULL
CD4	NULL
positive	NULL
T	NULL
cells	NULL
could	NULL
result	NULL
in	NULL
up-regulation	NULL
of	NULL
cytokines	NULL
containing	NULL
AP-1	NULL
sites	NULL
,	NULL
e.g	NULL
.	NULL

interleukin-3	NULL
and	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
and	NULL
concurrently	NULL
lead	NULL
to	NULL
T	NULL
cell	NULL
unresponsiveness	NULL
by	NULL
inhibiting	NULL
interleukin-2	NULL
secretion	NULL
.	NULL

The	NULL
CD4	NULL
molecule	NULL
is	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
via	NULL
the	NULL
envelope	NULL
glycoprotein	NULL
,	NULL
gp160/gp120	NULL
(	NULL
1	NULL
)	NULL
.	NULL

This	NULL
interaction	NULL
occurs	NULL
at	NULL
a	NULL
specific	NULL
region	NULL
at	NULL
the	NULL
external	NULL
domain	NULL
of	NULL
the	NULL
CD4	NULL
molecule	NULL
.	NULL

There	NULL
have	NULL
been	NULL
conflicting	NULL
reports	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
gp160/gp120	NULL
to	NULL
transduce	NULL
biochemical	NULL
signals	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

While	NULL
increase	NULL
in	NULL
intracellular	NULL
calcium	NULL
,	NULL
hydrolysis	NULL
of	NULL
phosphatidyl	NULL
inositol	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
tyrosine	NULL
kinases	NULL
have	NULL
been	NULL
demonstrated	NULL
by	NULL
some	NULL
(	NULL
2-5	NULL
)	NULL
,	NULL
others	NULL
have	NULL
failed	NULL
to	NULL
observe	NULL
these	NULL
events	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

The	NULL
interaction	NULL
of	NULL
the	NULL
CD4	NULL
molecule	NULL
with	NULL
the	NULL
nonpolymor-	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
Al	NULL
28281	NULL
(	NULL
to	NULL
S.	NULL
P.	NULL
)	NULL
and	NULL
AI	NULL
35414	NULL
(	NULL
to	NULL
N.	NULL
C.	NULL
)	NULL
.	NULL

The	NULL
electronic	NULL
mail	NULL
services	NULL
were	NULL
supported	NULL
by	NULL
clinical	NULL
research	NULL
Grant	NULL
MO1	NULL
RR	NULL
0047	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

{	NULL
To	NULL
whom	NULL
correspondence	NULL
may	NULL
be	NULL
addressed	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
516-562-4641	NULL
;	NULL
Fax	NULL
:	NULL
516-562-2866	NULL
.	NULL

§	NULL
Recipient	NULL
of	NULL
a	NULL
student	NULL
intern	NULL
award	NULL
from	NULL
the	NULL
Pediatric	NULL
AIDS	NULL
Foundation	NULL
.	NULL

phic	NULL
$	NULL
2	NULL
domain	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
molecule	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
play	NULL
a	NULL
vital	NULL
role	NULL
in	NULL
activation	NULL
of	NULL
mature	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
T	NULL
cell	NULL
development	NULL
in	NULL
the	NULL
thymus	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
now	NULL
demonstrated	NULL
that	NULL
the	NULL
CD4-MHC	NULL
class	NULL
II	NULL
interaction	NULL
is	NULL
essential	NULL
for	NULL
effective	NULL
signal	NULL
transduction	NULL
,	NULL
at	NULL
low	NULL
antigen	NULL
con-centrations	NULL
,	NULL
to	NULL
increase	NULL
the	NULL
avidity	NULL
,	NULL
in	NULL
co-receptor-dependent	NULL
systems	NULL
(	NULL
9	NULL
,	NULL
10	NULL
)	NULL
.	NULL

Studies	NULL
demonstrating	NULL
the	NULL
association	NULL
of	NULL
the	NULL
sre	NULL
homologous	NULL
tyrosine	NULL
kinase	NULL
p56	NULL
``	NULL
and	NULL
the	NULL
putative	NULL
p32	NULL
G-protein	NULL
with	NULL
the	NULL
cytoplasmic	NULL
tail	NULL
of	NULL
the	NULL
CD4	NULL
molecule	NULL
have	NULL
demonstrated	NULL
that	NULL
biochemical	NULL
signals	NULL
can	NULL
be	NULL
transduced	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

In	NULL
this	NULL
respect	NULL
,	NULL
exposure	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
to	NULL
anti-CD4	NULL
mAb	NULL
or	NULL
HIV	NULL
gp120	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
activation	NULL
of	NULL
the	NULL
Raf-l-related	NULL
110-kDa	NULL
polypeptide	NULL
,	NULL
and	NULL
phosphatidylinositol	NULL
3-	NULL
and	NULL
phosphatidylinositol	NULL
4-kinases	NULL
(	NULL
13	NULL
)	NULL
and	NULL
activation	NULL
of	NULL
NF-kB	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Utilizing	NULL
soluble	NULL
envelope	NULL
glycoproteins	NULL
of	NULL
HIV-1	NULL
,	NULL
gp160	NULL
,	NULL
we	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
CD4-mediated	NULL
signals	NULL
result	NULL
in	NULL
biological	NULL
effects	NULL
.	NULL

These	NULL
include	NULL
up-regulation	NULL
of	NULL
CD40	NULL
ligand	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
,	NULL
resulting	NULL
in	NULL
polyclonal	NULL
B	NULL
cell	NULL
differentiation	NULL
(	NULL
15	NULL
)	NULL
;	NULL
induction	NULL
of	NULL
IL-3	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
mRNA	NULL
and	NULL
cytokine	NULL
secretion	NULL
,	NULL
which	NULL
induce	NULL
increased	NULL
myelopoiesis	NULL
(	NULL
16	NULL
)	NULL
;	NULL
and	NULL
increased	NULL
expression	NULL
of	NULL
Fas	NULL
antigen	NULL
on	NULL
CD44	NULL
T	NULL
cells	NULL
,	NULL
resulting	NULL
in	NULL
accelerated	NULL
apoptosis	NULL
in	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
17	NULL
)	NULL
.	NULL

To	NULL
delineate	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
biochemical	NULL
signals	NULL
transduced	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
ability	NULL
of	NULL
gp160	NULL
and	NULL
anti-CD4	NULL
mAbs	NULL
to	NULL
induce	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
,	NULL
activated	NULL
protein	NULL
1	NULL
(	NULL
AP-1	NULL
)	NULL
.	NULL

Physiological	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
results	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
AP-1	NULL
(	NULL
18	NULL
)	NULL
.	NULL

AP-1	NULL
is	NULL
a	NULL
collection	NULL
of	NULL
homodimeric	NULL
and	NULL
heterodimeric	NULL
protein	NULL
complexes	NULL
of	NULL
the	NULL
c-fos	NULL
and	NULL
c-jun	NULL
proto-oncogene	NULL
products	NULL
(	NULL
19	NULL
)	NULL
.	NULL

These	NULL
proteins	NULL
interact	NULL
with	NULL
a	NULL
common	NULL
DNA	NULL
binding	NULL
site	NULL
,	NULL
the	NULL
TPA-responsive	NULL
element	NULL
(	NULL
TGACC/G	NULL
)	NULL
TCA	NULL
)	NULL
and	NULL
activate	NULL
gene	NULL
transcription	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
AP-1	NULL
to	NULL
the	NULL
TPA-responsive	NULL
element	NULL
has	NULL
been	NULL
attributed	NULL
to	NULL
post-translational	NULL
modification	NULL
of	NULL
preexisting	NULL
members	NULL
of	NULL
the	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
of	NULL
proteins	NULL
,	NULL
involving	NULL
phosphorylation	NULL
and	NULL
dephosphorylation	NULL
events	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
CD4-induced	NULL
signals	NULL
transduced	NULL
by	NULL
gp160	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
gp160	NULL
in	NULL
T	NULL
cells	NULL
result	NULL
in	NULL
activation	NULL
of	NULL
AP-1	NULL
by	NULL
a	NULL
mechanism	NULL
that	NULL
involves	NULL
post-translational	NULL
activation	NULL
of	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

Depression	NULL
of	NULL
antigen-specific	NULL
T	NULL
cell	NULL
responses	NULL
is	NULL
a	NULL
relatively	NULL
early	NULL
feature	NULL
of	NULL
HIV	NULL
infection	NULL
and	NULL
precedes	NULL
the	NULL
quantitative	NULL
decline	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Several	NULL
investigators	NULL
have	NULL
clearly	NULL
demonstrated	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
gp120	NULL
on	NULL
normal	NULL
T	NULL
cell	NULL
'	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
MHC	NULL
,	NULL
major	NULL
histocompatibility	NULL
class	NULL
;	NULL
HIV	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
;	NULL
AP-1	NULL
,	NULL
activated	NULL
protein-1	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
.	NULL

19364	NULL
functions	NULL
(	NULL
for	NULL
review	NULL
,	NULL
see	NULL
Ref	NULL
.	NULL

23	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
gp120-mediated	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
responses	NULL
involves	NULL
inhibition	NULL
of	NULL
intracellular	NULL
calcium	NULL
mobilization	NULL
,	NULL
hydrolysis	NULL
of	NULL
inositol	NULL
phos-phates	NULL
,	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
and	NULL
kinase	NULL
activity	NULL
of	NULL
p56	NULL
``	NULL
*	NULL
(	NULL
24-28	NULL
)	NULL
.	NULL

The	NULL
reduced	NULL
proliferative	NULL
responses	NULL
were	NULL
attributed	NULL
to	NULL
inhibition	NULL
of	NULL
decreased	NULL
IL-2	NULL
mRNA	NULL
expression	NULL
and	NULL
IL-2	NULL
secretion	NULL
(	NULL
25	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
suggested	NULL
that	NULL
binding	NULL
of	NULL
envelope	NULL
glycoproteins	NULL
of	NULL
HIV	NULL
to	NULL
CD4+	NULL
T	NULL
cells	NULL
induces	NULL
aberrant	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
(	NULL
which	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
IL-2	NULL
gene	NULL
transcription	NULL
,	NULL
Ref	NULL
.	NULL

18	NULL
)	NULL
and	NULL
results	NULL
in	NULL
inhibition	NULL
anti-CD3	NULL
mAb-induced	NULL
IL-2	NULL
secretion	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Envelope	NULL
Glycoproteins-gp160	NULL
and	NULL
gp120	NULL
were	NULL
purified	NULL
from	NULL
culture	NULL
supernatants	NULL
of	NULL
a	NULL
clone	NULL
of	NULL
HIV-infected	NULL
Hut-78	NULL
cells	NULL
,	NULL
6D4	NULL
;	NULL
,	NULL
;	NULL
,	NULL
,	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
supernatant	NULL
of	NULL
cells	NULL
grown	NULL
in	NULL
serum-free	NULL
HB104	NULL
medium	NULL
was	NULL
concentrated	NULL
and	NULL
passed	NULL
through	NULL
a	NULL
lentil-lectin	NULL
Sepharose	NULL
column	NULL
.	NULL

Glycoproteins	NULL
were	NULL
eluted	NULL
with	NULL
400	NULL
mM	NULL
«	NULL
-methyl	NULL
mannoside	NULL
.	NULL

gp160	NULL
was	NULL
further	NULL
purified	NULL
by	NULL
affinity	NULL
chromatography	NULL
over	NULL
anti-HIV	NULL
,	NULL
,	NULL
,	NULL
mAb-Sepharose	NULL
4B	NULL
column	NULL
.	NULL

The	NULL
envelope	NULL
glycoprotein	NULL
preparations	NULL
were	NULL
>	NULL
95	NULL
%	NULL
pure	NULL
and	NULL
were	NULL
not	NULL
contaminated	NULL
with	NULL
endo-toxins	NULL
,	NULL
as	NULL
tested	NULL
by	NULL
the	NULL
Limulus	NULL
amoebocyte	NULL
lysate	NULL
assay	NULL
(	NULL
E-TOXATE	NULL
,	NULL
Sigma	NULL
)	NULL
.	NULL

Antibodies	NULL
and	NULL
Reagents-The	NULL
following	NULL
reagents	NULL
and	NULL
resources	NULL
were	NULL
used	NULL
:	NULL
mAb	NULL
to	NULL
CD4	NULL
(	NULL
Leusa	NULL
,	NULL
IgG1	NULL
;	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountainview	NULL
,	NULL
CA	NULL
)	NULL
;	NULL
mAb	NULL
to	NULL
CD3	NULL
(	NULL
mAb	NULL
454	NULL
,	NULL
IgG2a	NULL
,	NULL
gift	NULL
from	NULL
Dr.	NULL
N.	NULL
Chiorazzi	NULL
,	NULL
North	NULL
Shore	NULL
University	NULL
Hospital	NULL
,	NULL
Manhasset	NULL
,	NULL
NY	NULL
)	NULL
;	NULL
nonimmune	NULL
mouse	NULL
Ig	NULL
(	NULL
mig	NULL
;	NULL
Chrompure	NULL
IgG	NULL
,	NULL
Jackson	NULL
ImmunoResearch	NULL
,	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Polyclonal	NULL
antibodies	NULL
to	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
used	NULL
were	NULL
as	NULL
follows	NULL
;	NULL
rabbit	NULL
anti-c-Jun/AP1	NULL
and	NULL
anti-c-Fos	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechologies	NULL
,	NULL
Santa	NULL
Crus	NULL
,	NULL
CA	NULL
)	NULL
recognize	NULL
all	NULL
of	NULL
the	NULL
members	NULL
of	NULL
the	NULL
Fos/Jun	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

Polyclonal	NULL
rabbit	NULL
anti-gp120	NULL
,	NULL
;	NULL
,	NULL
was	NULL
developed	NULL
by	NULL
Advanced	NULL
BioScience	NULL
Labs	NULL
Inc.	NULL
,	NULL
Kensington	NULL
,	NULL
MD	NULL
;	NULL
soluble	NULL
CD4-IgG	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Genentech	NULL
,	NULL
San	NULL
Fransisco	NULL
,	NULL
CA	NULL
.	NULL

Herbimycin	NULL
A	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
cyclosporine	NULL
A	NULL
(	NULL
Sandoz	NULL
,	NULL
East	NULL
Hanover	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
H-7	NULL
,	NULL
cycloheximide	NULL
,	NULL
2-mer-captoethanol	NULL
,	NULL
verapamil	NULL
,	NULL
and	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Cells-CD4	NULL
positive	NULL
clone	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
E6-1	NULL
,	NULL
obtained	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
AIDS	NULL
Reference	NULL
Reagent	NULL
Program	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
,	NULL
(	NULL
donated	NULL
by	NULL
Dr.	NULL
A.	NULL
Weiss	NULL
,	NULL
Ref	NULL
.	NULL

29	NULL
)	NULL
was	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Whittaker	NULL
)	NULL
supplemented	NULL
with	NULL
pennicillin	NULL
and	NULL
streptomycin	NULL
and	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

CD4	NULL
positive	NULL
T	NULL
cells	NULL
H9	NULL
,	NULL
Molt4	NULL
were	NULL
obtained	NULL
from	NULL
ATCC	NULL
,	NULL
Betheda	NULL
,	NULL
MD	NULL
.	NULL

CD4	NULL
negative	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
JN	NULL
)	NULL
were	NULL
mutant	NULL
CD4	NULL
negative	NULL
(	NULL
CD3+	NULL
)	NULL
cells	NULL
by	NULL
fluorescence-activated	NULL
cell	NULL
sorting	NULL
analysis	NULL
following	NULL
staining	NULL
with	NULL
fluorescein	NULL
isothiocyanate-conjugated	NULL
anti-CD3	NULL
mAb	NULL
and	NULL
anti-CD4-conjugated	NULL
with	NULL
phycoerythrin	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Mountainview	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Peripheral	NULL
blood	NULL
lymphocytes	NULL
were	NULL
purified	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
purified	NULL
from	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
by	NULL
rosetting	NULL
2	NULL
times	NULL
with	NULL
neuraminidase-treated	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
as	NULL
described	NULL
earlier	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Immunomagnetic	NULL
Separation	NULL
of	NULL
CD4+	NULL
and	NULL
CD8+	NULL
T	NULL
Cells-Purified	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
or	NULL
with	NULL
gp160	NULL
for	NULL
4	NULL
h	NULL
were	NULL
incubated	NULL
with	NULL
anti-CD8	NULL
mAb	NULL
conjugated	NULL
immunomagnetic	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Great	NULL
Neck	NULL
,	NULL
NY	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
on	NULL
a	NULL
rotating	NULL
shaker	NULL
,	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
subjected	NULL
to	NULL
a	NULL
magnetic	NULL
field	NULL
,	NULL
and	NULL
the	NULL
unbound	NULL
cells	NULL
(	NULL
designated	NULL
CD8	NULL
negative	NULL
,	NULL
CD8-	NULL
T	NULL
cells	NULL
)	NULL
were	NULL
carefully	NULL
aspirated	NULL
.	NULL

The	NULL
cells	NULL
bound	NULL
to	NULL
the	NULL
beads	NULL
were	NULL
designated	NULL
CD8	NULL
positive	NULL
(	NULL
CD8+	NULL
)	NULL
and	NULL
were	NULL
>	NULL
90	NULL
%	NULL
CD4+	NULL
as	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
as	NULL
described	NULL
below	NULL
.	NULL

Nuclear	NULL
Extracts-Small	NULL
scale	NULL
nuclear	NULL
extracts	NULL
were	NULL
made	NULL
from	NULL
2	NULL
x	NULL
10	NULL
``	NULL
unactivated	NULL
or	NULL
activated	NULL
E6-1	NULL
cells	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Unless	NULL
otherwise	NULL
stated	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
or	NULL
various	NULL
stimuli	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
10	NULL
mit	NULL
Tris	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
10	NULL
mm	NULL
NaCl	NULL
,	NULL
3	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mit	NULL
dithiothreitol	NULL
and	NULL
0.5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
and	NULL
lysed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
Nonidet	NULL
P-40	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.5	NULL
%	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
and	NULL
washed	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
without	NULL
Nonidet	NULL
P-40	NULL
,	NULL
and	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
in	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
mit	NULL
0.42	NULL
NaCl	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mm	NULL
EDTA	NULL
,	NULL
25	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
0.01	NULL
%	NULL
NaN	NULL
,	NULL
)	NULL
(	NULL
30	NULL
)	NULL
.	NULL

After	NULL
pelleting	NULL
neclear	NULL
debris	NULL
,	NULL
the	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
diluted	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
buffer	NULL
D	NULL
(	NULL
20	NULL
mm	NULL
HEPES	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
50	NULL
mm	NULL
KCl	NULL
,	NULL
0.2	NULL
mm	NULL
EDTA	NULL
,	NULL
20	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
0.01	NULL
%	NULL
NaN	NULL
,	NULL
)	NULL
.	NULL

This	NULL
extract	NULL
was	NULL
used	NULL
directly	NULL
in	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
.	NULL

The	NULL
equivalence	NULL
of	NULL
the	NULL
extracts	NULL
was	NULL
verified	NULL
by	NULL
protein	NULL
estimation	NULL
using	NULL
the	NULL
BCA	NULL
protein	NULL
kit	NULL
(	NULL
Pierce	NULL
)	NULL
.	NULL

19365	NULL
<	NULL
€	NULL
AP	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
900	NULL
40	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Stimulation	NULL
of	NULL
CD4	NULL
positive	NULL
T	NULL
cells	NULL
with	NULL
gp160	NULL
induces	NULL
AP-1	NULL
activation	NULL
.	NULL

Stimulation	NULL
of	NULL
E6-1	NULL
cells	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
medium	NULL
alone	NULL
(	NULL
Zane	NULL
1	NULL
,	NULL
unsti	NULL
)	NULL
or	NULL
various	NULL
concentrations	NULL
of	NULL
gp160	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
)	NULL
and	NULL
gp120	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
1	NULL
ug/ml	NULL
of	NULL
anti-CD4	NULL
mAb	NULL
(	NULL
Leu3a	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
or	NULL
50	NULL
ng/ml	NULL
PMA	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
,	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

Lane	NULL
10	NULL
comprised	NULL
of	NULL
competition	NULL
of	NULL
AP-1	NULL
binding	NULL
by	NULL
10	NULL
x	NULL
cold	NULL
AP-1	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
IL-2	NULL
AP-1	NULL
site	NULL
.	NULL

The	NULL
hollow	NULL
arrow	NULL
indicates	NULL
mobility	NULL
of	NULL
free	NULL
probe	NULL
,	NULL
and	NULL
the	NULL
solid	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
specific	NULL
AP-1	NULL
binding	NULL
.	NULL

The	NULL
result	NULL
is	NULL
a	NULL
representative	NULL
of	NULL
at	NULL
least	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

EMSA-Double-stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
consensus	NULL
AP-1	NULL
binding	NULL
sequence	NULL
TTG	NULL
ATG	NULL
AGT	NULL
CAG	NULL
CGC	NULL
GAA-3	NULL
'	NULL
(	NULL
31	NULL
)	NULL
)	NULL
were	NULL
obtained	NULL
commercially	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
and	NULL
end-labeled	NULL
with	NULL
[	NULL
y*P	NULL
]	NULL
JATP	NULL
and	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
the	NULL
binding	NULL
site	NULL
of	NULL
AP-1	NULL
to	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
(	NULL
5'-AATTCCAAAGAGTCATCAGA-3	NULL
'	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
competitor	NULL
(	NULL
18	NULL
)	NULL
.	NULL

For	NULL
each	NULL
binding	NULL
reaction	NULL
,	NULL
10,000	NULL
cpm	NULL
(	NULL
0.2-0.5	NULL
ng	NULL
)	NULL
of	NULL
end-labeled	NULL
oligonu-cleotide	NULL
was	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
with	NULL
5-8	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
mg	NULL
of	NULL
sheared	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Phar-macia	NULL
Biotech	NULL
Inc.	NULL
)	NULL
.	NULL

The	NULL
resulting	NULL
DNA-protein	NULL
complexes	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoresis	NULL
at	NULL
4	NULL
°C	NULL
of	NULL
4	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Unlabeled	NULL
oligonucleotides	NULL
used	NULL
for	NULL
competitions	NULL
were	NULL
added	NULL
to	NULL
nuclear	NULL
extracts	NULL
and	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
labeled	NULL
probe	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
on	NULL
a	NULL
gel	NULL
drier	NULL
(	NULL
Bio-Rad	NULL
)	NULL
and	NULL
visualized	NULL
by	NULL
autoradiography	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
antibodies	NULL
to	NULL
¢-Jun	NULL
,	NULL
c-Fos	NULL
,	NULL
or	NULL
normal	NULL
rabbit	NULL
serum	NULL
for	NULL
1	NULL
h	NULL
on	NULL
ice	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
Protein	NULL
A-conjugated	NULL
Sepharose	NULL
(	NULL
Pharmacia	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

After	NULL
centrifugation	NULL
at	NULL
5000	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
,	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
AP-1	NULL
binding	NULL
in	NULL
EMSA	NULL
,	NULL
as	NULL
described	NULL
above	NULL
.	NULL

IL-2	NULL
Secretion-CD4+	NULL
E6-1	NULL
cells	NULL
,	NULL
CD4-	NULL
JN	NULL
cells	NULL
,	NULL
or	NULL
purified	NULL
CD4+	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
medium	NULL
,	NULL
various	NULL
concentrations	NULL
of	NULL
gp120	NULL
,	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
(	NULL
mAb	NULL
Leusa	NULL
)	NULL
followed	NULL
by	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
mAb	NULL
454	NULL
)	NULL
plus	NULL
10	NULL
ng/ml	NULL
PMA	NULL
for	NULL
24	NULL
h.	NULL
Culture	NULL
supernatants	NULL
were	NULL
collected	NULL
and	NULL
analyzed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
IL-2	NULL
by	NULL
commercial	NULL
ELISA	NULL
kit	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Minneapolis	NULL
,	NULL
MN	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

RESULTS	NULL
gp160-induced	NULL
AP-1	NULL
Activation	NULL
in	NULL
CD4+	NULL
T	NULL
Cells-Fig	NULL
.	NULL

1	NULL
shows	NULL
that	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
AP-1	NULL
activation	NULL
in	NULL
the	NULL
CD4+	NULL
E6-1	NULL
cells	NULL
could	NULL
be	NULL
enhanced	NULL
by	NULL
stimulation	NULL
with	NULL
gp160	NULL
at	NULL
a	NULL
concentration	NULL
as	NULL
low	NULL
as	NULL
0.01	NULL
mg/ml	NULL
.	NULL

This	NULL
concentration	NULL
of	NULL
envelope	NULL
proteins	NULL
has	NULL
been	NULL
previously	NULL
reported	NULL
in	NULL
the	NULL
serum	NULL
of	NULL
HIV-infected	NULL
individuals	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Soluble	NULL
gp120	NULL
,	NULL
anti-CD4	NULL
mAb	NULL
(	NULL
Leu3a	NULL
)	NULL
and	NULL
PMA	NULL
alone	NULL
could	NULL
also	NULL
induce	NULL
activation	NULL
of	NULL
AP-1	NULL
in	NULL
the	NULL
CD4+	NULL
E6-1	NULL
cells	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
demonstrated	NULL
by	NULL
abrogation	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
excess	NULL
unlabeled	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
competitor	NULL
,	NULL
lane	NULL
10	NULL
)	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
proteins	NULL
was	NULL
examined	NULL
by	NULL
using	NULL
nuclear	NULL
extracts	NULL
from	NULL
19366	NULL
6	NULL
x8	NULL
go	NULL
1A	NULL
“	NULL
$	NULL
@	NULL
99	NULL
10	NULL
20	NULL
3	NULL
4	NULL
50	NULL
60	NULL
7	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Kinetics	NULL
of	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
activation	NULL
.	NULL

E6-1	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
mg/ml	NULL
gp160	NULL
for	NULL
various	NULL
time	NULL
intervals	NULL
indicated	NULL
.	NULL

AP-1	NULL
binding	NULL
was	NULL
analyzed	NULL
by	NULL
EMSA	NULL
.	NULL

The	NULL
lower	NULL
band	NULL
shows	NULL
nonspecific	NULL
binding	NULL
(	NULL
ns	NULL
)	NULL
.	NULL

E6-1	NULL
cells	NULL
stimulated	NULL
for	NULL
increasing	NULL
amounts	NULL
of	NULL
time	NULL
.	NULL

The	NULL
gp160-induced	NULL
AP-1	NULL
binding	NULL
was	NULL
observed	NULL
within	NULL
30	NULL
min	NULL
,	NULL
peaked	NULL
at	NULL
4	NULL
h	NULL
,	NULL
persisted	NULL
for	NULL
24	NULL
h	NULL
of	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
gp160-induced	NULL
AP-1	NULL
binding	NULL
was	NULL
specific	NULL
,	NULL
since	NULL
it	NULL
could	NULL
be	NULL
abrogated	NULL
by	NULL
pretreatment	NULL
of	NULL
gp160	NULL
with	NULL
goat	NULL
anti-gp120	NULL
polyclonal	NULL
antibody	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
;	NULL
normal	NULL
goat	NULL
serum	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
stimulatory	NULL
effect	NULL
of	NULL
gp160	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

That	NULL
the	NULL
constituents	NULL
of	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
complex	NULL
comprises	NULL
Jun	NULL
and	NULL
Fos	NULL
components	NULL
was	NULL
confirmed	NULL
by	NULL
abrogation	NULL
of	NULL
AP-1	NULL
binding	NULL
by	NULL
immunoprecipitation	NULL
of	NULL
the	NULL
gp160-stimulated	NULL
nuclear	NULL
extracts	NULL
with	NULL
polyclonal	NULL
antibodies	NULL
to	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
;	NULL
even	NULL
the	NULL
basal	NULL
level	NULL
binding	NULL
of	NULL
AP-1	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
these	NULL
antibod-ies	NULL
.	NULL

Normal	NULL
rabbit	NULL
serum	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
binding	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
gp160	NULL
can	NULL
induce	NULL
activation	NULL
of	NULL
AP-1	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
and	NULL
that	NULL
the	NULL
AP-1	NULL
complex	NULL
consists	NULL
of	NULL
Fos/Jun	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

The	NULL
gp160-induced	NULL
Activation	NULL
of	NULL
AP-1	NULL
Was	NULL
Mediated	NULL
through	NULL
the	NULL
CD4	NULL
Molecule-In	NULL
order	NULL
to	NULL
demonstrate	NULL
that	NULL
the	NULL
cell	NULL
surface	NULL
molecule	NULL
involved	NULL
in	NULL
the	NULL
gp160-mediated	NULL
stimulatory	NULL
effects	NULL
was	NULL
CD4	NULL
,	NULL
gp160	NULL
was	NULL
first	NULL
preincubated	NULL
with	NULL
soluble	NULL
CD4-	NULL
IgG	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
,	NULL
prior	NULL
to	NULL
addition	NULL
to	NULL
the	NULL
cell	NULL
cultures	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
shows	NULL
that	NULL
the	NULL
stimulatory	NULL
activity	NULL
of	NULL
gp160	NULL
on	NULL
E6G-1	NULL
cells	NULL
could	NULL
be	NULL
abrogated	NULL
by	NULL
pretreatment	NULL
of	NULL
gp160	NULL
with	NULL
soluble	NULL
CD4-IgG	NULL
(	NULL
compare	NULL
lane	NULL
2	NULL
with	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

An	NULL
irrelevant	NULL
protein	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
did	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
gp160-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
further	NULL
demonstrate	NULL
that	NULL
gp160-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
was	NULL
mediated	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
,	NULL
CD4+	NULL
and	NULL
CD4	NULL
negative	NULL
T	NULL
cell	NULL
lines	NULL
were	NULL
analyzed	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
shows	NULL
that	NULL
gp160	NULL
could	NULL
stimulate	NULL
AP-1	NULL
activation	NULL
in	NULL
CD4+	NULL
H9	NULL
cells	NULL
,	NULL
Molt4	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
CD4	NULL
negative	NULL
mutant	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
JN	NULL
)	NULL
.	NULL

Here	NULL
again	NULL
,	NULL
pretreatment	NULL
of	NULL
gp160	NULL
with	NULL
soluble	NULL
CD4	NULL
abrogated	NULL
AP-1	NULL
activation	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

All	NULL
of	NULL
these	NULL
cells	NULL
could	NULL
be	NULL
effectively	NULL
induce	NULL
AP-1	NULL
activation	NULL
upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
the	NULL
stimulatory	NULL
activity	NULL
of	NULL
gp160	NULL
on	NULL
AP-1	NULL
activation	NULL
is	NULL
mediated	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
.	NULL

Gp160	NULL
Induced	NULL
AP-1	NULL
Activation	NULL
in	NULL
Peripheral	NULL
Blood	NULL
CD4+	NULL
T	NULL
Cells-In	NULL
order	NULL
to	NULL
determine	NULL
the	NULL
ability	NULL
of	NULL
gp160	NULL
to	NULL
activate	NULL
physiological	NULL
cells	NULL
and	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
,	NULL
purified	NULL
T	NULL
cells	NULL
were	NULL
first	NULL
stimulated	NULL
with	NULL
gp160	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

CD4+	NULL
T	NULL
cells	NULL
were	NULL
separated	NULL
from	NULL
CD8+	NULL
T	NULL
cells	NULL
by	NULL
negative	NULL
selection	NULL
using	NULL
anti-CD8	NULL
mAb-conjugated	NULL
magnetic	NULL
beads	NULL
;	NULL
cells	NULL
bound	NULL
to	NULL
the	NULL
beads	NULL
were	NULL
designated	NULL
CD8+	NULL
,	NULL
and	NULL
unbound	NULL
T	NULL
cells	NULL
designated	NULL
CD8-	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
shows	NULL
that	NULL
stimulation	NULL
of	NULL
CD8-	NULL
T	NULL
cells	NULL
(	NULL
>	NULL
90	NULL
%	NULL
CD4+	NULL
by	NULL
flow	NULL
cytometry	NULL
)	NULL
with	NULL
gp160	NULL
induced	NULL
AP-1	NULL
activation	NULL
(	NULL
upper	NULL
right	NULL
panel	NULL
)	NULL
no	NULL
activation	NULL
of	NULL
AP-1	NULL
occurred	NULL
in	NULL
the	NULL
CD8+	NULL
T	NULL
cells	NULL
(	NULL
upper	NULL
left	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
stimulatory	NULL
effects	NULL
of	NULL
gp160	NULL
on	NULL
CD8-	NULL
T	NULL
cells	NULL
could	NULL
be	NULL
abrogated	NULL
by	NULL
pretreatment	NULL
of	NULL
gp160	NULL
with	NULL
soluble	NULL
CD4-	NULL
IgG	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

Soluble	NULL
CD4-	NULL
IgG	NULL
itself	NULL
did	NULL
not	NULL
induce	NULL
activation	NULL
of	NULL
AP-1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Signal	NULL
Requirements	NULL
for	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
Activa-	NULL
HIV-1	NULL
Glycoproteins	NULL
Induce	NULL
Activation	NULL
of	NULL
AP-1	NULL
in	NULL
CD4+	NULL
T	NULL
Cells	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Pretreatment	NULL
of	NULL
gp160	NULL
with	NULL
soluble	NULL
CD4-IgG	NULL
or	NULL
anti-gp160	NULL
antibodies	NULL
abrogates	NULL
its	NULL
activity	NULL
.	NULL

E6-1	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
Zane	NULL
1	NULL
,	NULL
unsti	NULL
)	NULL
or	NULL
1	NULL
ug/ml	NULL
gp160	NULL
(	NULL
lanes	NULL
2-8	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
or	NULL
1	NULL
ug/ml	NULL
soluble	NULL
CD4-IgG	NULL
(	NULL
Genentech	NULL
,	NULL
CA	NULL
)	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
)	NULL
or	NULL
1	NULL
ug/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
(	NULL
Zane	NULL
5	NULL
)	NULL
,	NULL
1:1000	NULL
,	NULL
1:3000	NULL
dilution	NULL
of	NULL
polyclonal	NULL
goat	NULL
anti-gp160	NULL
antibodies	NULL
(	NULL
Zanes	NULL
6	NULL
and	NULL
7	NULL
)	NULL
,	NULL
or	NULL
1:1000	NULL
dilution	NULL
of	NULL
normal	NULL
goat	NULL
serum	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

EMSA	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

The	NULL
gp160-induced	NULL
AP-1	NULL
complex	NULL
contains	NULL
Fos	NULL
and	NULL
Jun	NULL
family	NULL
of	NULL
proteins	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
generated	NULL
from	NULL
E6G-1	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
Zane	NULL
1	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
1	NULL
ug/ml	NULL
gp160	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
(	NULL
lanes	NULL
2-8	NULL
)	NULL
.	NULL

The	NULL
gp160-induced	NULL
nuclear	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
medium	NULL
(	NULL
Zanes	NULL
I	NULL
and	NULL
2	NULL
)	NULL
,	NULL
1	NULL
ug	NULL
(	NULL
in	NULL
1	NULL
pl	NULL
)	NULL
,	NULL
or	NULL
0.1	NULL
ug	NULL
(	NULL
in	NULL
0.1	NULL
pl	NULL
)	NULL
of	NULL
antibodies	NULL
to	NULL
Fos	NULL
and	NULL
Jun	NULL
proteins	NULL
(	NULL
which	NULL
recognize	NULL
all	NULL
of	NULL
the	NULL
members	NULL
of	NULL
the	NULL
Fos/Jun	NULL
family	NULL
of	NULL
proteins	NULL
)	NULL
or	NULL
normal	NULL
rabbit	NULL
serum	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Immune	NULL
complexes	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
Protein	NULL
A-Sepha-rose	NULL
beads	NULL
(	NULL
Pharmacia	NULL
)	NULL
,	NULL
and	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
AP-1	NULL
binding	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
five	NULL
separate	NULL
experiments	NULL
.	NULL

u	NULL
_	NULL
9	NULL
o	NULL
£	NULL
&	NULL
£	NULL
o	NULL
&	NULL
«	NULL
P	NULL
R	NULL
0	NULL
x	NULL
ba	NULL
B	NULL
2s	NULL
3	NULL
P.	NULL
6	NULL
N	NULL
N	NULL
A	NULL
CCJ	NULL
C	NULL
C	NULL
4	NULL
¢	NULL
g	NULL
o	NULL
o	NULL
Wid	NULL
aa	NULL
=	NULL
4	NULL
sea	NULL
i	NULL
Nco	NULL
filam	NULL
at	NULL
sgh	NULL
:	NULL
|	NULL
1	NULL
2	NULL
3	NULL
4	NULL
50	NULL
6	NULL
7	NULL
s	NULL
9	NULL
10	NULL
CB	NULL
Es-m	NULL
P	NULL
co	NULL
>	NULL
c9°	NULL
``	NULL
&	NULL
»	NULL
&	NULL
x	NULL
x*	NULL
``	NULL
x	NULL
C	NULL
leo	NULL
P	NULL
&	NULL
p	NULL
®	NULL
NO	NULL
XF	NULL
up	NULL
q	NULL
‘	NULL
t	NULL
‘	NULL
00a	NULL
“	NULL
QQN	NULL
®	NULL
®	NULL
#	NULL
Q	NULL
‘	NULL
x	NULL
‘	NULL
x	NULL
o	NULL
p	NULL
10	NULL
-P	NULL
°	NULL
®	NULL
«	NULL
@	NULL
@	NULL
€	NULL
@	NULL
I	NULL
wo	NULL
4	NULL
apa	NULL
1	NULL
2	NULL
3	NULL
4	NULL
506	NULL
7	NULL
8s	NULL
9	NULL
40	NULL
f	NULL
12	NULL
0	NULL
Molt	NULL
4	NULL
JN	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

CD4	NULL
positive	NULL
T	NULL
cell	NULL
lines	NULL
,	NULL
but	NULL
not	NULL
CD4	NULL
negative	NULL
T	NULL
cell	NULL
lines	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
gp160	NULL
to	NULL
increase	NULL
AP-1	NULL
activation	NULL
.	NULL

H9	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
,	NULL
unst	NULL
?	NULL
)	NULL

,	NULL
or	NULL
with	NULL
PMA	NULL
,	NULL
gp160	NULL
,	NULL
or	NULL
gp120	NULL
(	NULL
lanes	NULL
2	NULL
,	NULL
3	NULL
,	NULL
and	NULL
4	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
soluble	NULL
CD4	NULL
IgG	NULL
(	NULL
lanes	NULL
5	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
)	NULL
;	NULL
E6-1	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
,	NULL
PMA	NULL
and	NULL
gp160	NULL
(	NULL
lanes	NULL
9	NULL
and	NULL
10	NULL
)	NULL
as	NULL
positive	NULL
controls	NULL
.	NULL

CD4	NULL
positive	NULL
Molt4	NULL
and	NULL
CD4	NULL
negative	NULL
JN	NULL
(	NULL
mutant	NULL
CD4	NULL
negative	NULL
Jurkat	NULL
cells	NULL
)	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
Zanes	NULL
1	NULL
and	NULL
7	NULL
,	NULL
unsti	NULL
)	NULL
,	NULL
gp160	NULL
,	NULL
gp120	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
and	NULL
lanes	NULL
8	NULL
and	NULL
9	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
soluble	NULL
CD4-IgG	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
and	NULL
lanes	NULL
10	NULL
and	NULL
11	NULL
)	NULL
or	NULL
PMA	NULL
alone	NULL
(	NULL
lanes	NULL
6	NULL
and	NULL
12	NULL
)	NULL
.	NULL

tion-In	NULL
order	NULL
to	NULL
investigate	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
signals	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
AP-1	NULL
by	NULL
gp160	NULL
,	NULL
several	NULL
pharmacological	NULL
inhibitors	NULL
were	NULL
utilized	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
shows	NULL
that	NULL
addition	NULL
of	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
,	NULL
inhibitor	NULL
of	NULL
tyrosine	NULL
phosphorylation	NULL
)	NULL
,	NULL
and	NULL
H7	NULL
(	NULL
in-hibitor	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
)	NULL
abrogated	NULL
gp160-induced	NULL
AP-1	NULL
HIV-1	NULL
Glycoproteins	NULL
Induce	NULL
Activation	NULL
of	NULL
AP-1	NULL
in	NULL
CD4+	NULL
T	NULL
Cells	NULL
A	NULL
a	NULL
8	NULL
a	NULL
C	NULL
8	NULL
<	NULL
£	NULL
€	NULL
C	NULL
628	NULL
0	NULL
C	NULL
&	NULL
C	NULL
C	NULL
<	NULL
P	NULL
°	NULL
J	NULL
$	NULL
°	NULL
J	NULL
J	NULL
J	NULL
``	NULL
x	NULL
¢	NULL
¢	NULL
8	NULL
a	NULL
§	NULL
3	NULL
``	NULL
a	NULL
``	NULL
a	NULL
``	NULL
'	NULL
&	NULL
``	NULL
»	NULL
``	NULL
s	NULL
``	NULL
'	NULL
o	NULL
&	NULL
FEP	NULL
P	NULL
&	NULL
$	NULL
0	NULL
P	NULL
P	NULL
¢	NULL
¢	NULL
¢	NULL
$	NULL
$	NULL
S	NULL
$	NULL
$	NULL
&	NULL
&	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
CD8+	NULL
T	NULL
cells	NULL
CD8-	NULL
T	NULL
cells	NULL
>	NULL
>	NULL
O	NULL
O	NULL
s	NULL
o	NULL
6c	NULL
}	NULL
tbs-j	NULL
2	NULL
C	NULL
uo	NULL
,	NULL
P	NULL
uP	NULL
&	NULL
®	NULL
X	NULL
X	NULL
w	NULL
V	NULL
¢	NULL
$	NULL
$	NULL
$	NULL
43	NULL
tw	NULL
=	NULL
C	NULL
tous	NULL
ta	NULL
Sl	NULL
ins	NULL
1	NULL
2	NULL
$	NULL
4	NULL
5	NULL
6	NULL
CD8-	NULL
T	NULL
cells	NULL
Fic	NULL
.	NULL

6.	NULL
gp160	NULL
can	NULL
induce	NULL
CD8-	NULL
but	NULL
not	NULL
CD8+	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
to	NULL
induce	NULL
AP-1	NULL
binding	NULL
.	NULL

Upper	NULL
panel	NULL
,	NULL
purified	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
,	NULL
unsti	NULL
)	NULL
,	NULL
1	NULL
ug/ml	NULL
gp160	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
,	NULL
or	NULL
gp120	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
.	NULL

CD4	NULL
and	NULL
CD8	NULL
positive	NULL
T	NULL
cells	NULL
were	NULL
separated	NULL
by	NULL
anti-CD8	NULL
mAb-conjugated	NULL
magnetic	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Great	NULL
Neck	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

Adherent	NULL
cells	NULL
were	NULL
denoted	NULL
CD8	NULL
positive	NULL
and	NULL
nonadherent	NULL
cells	NULL
as	NULL
CD4	NULL
positive	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
assessed	NULL
for	NULL
AP-1	NULL
binding	NULL
by	NULL
EMSA	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
specific	NULL
binding	NULL
for	NULL
AP-1	NULL
,	NULL
and	NULL
the	NULL
lower	NULL
band	NULL
indicates	NULL
nonspecific	NULL
binding	NULL
(	NULL
ns	NULL
)	NULL
.	NULL

Lower	NULL
panel	NULL
,	NULL
gp160	NULL
induced	NULL
AP-1	NULL
binding	NULL
in	NULL
CD4+	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
abrogated	NULL
by	NULL
soluble	NULL
CD4-	NULL
IgG	NULL
.	NULL

Purified	NULL
T	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
lane	NULL
1	NULL
,	NULL
unsti	NULL
)	NULL
or	NULL
1	NULL
ug/ml	NULL
gp160	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
)	NULL
or	NULL
gp120	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
5	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
soluble	NULL
CD4-IgG	NULL
(	NULL
Zanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
;	NULL
50	NULL
ng/ml	NULL
PMA	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

I	NULL
‘	NULL
SIuclear	NULL
extracts	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
AP-1	NULL
binding	NULL
by	NULL
EMSA	NULL
.	NULL

1	NULL
2	NULL
8	NULL
4	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

The	NULL
gp160-mediated	NULL
AP-1	NULL
binding	NULL
is	NULL
dependent	NULL
on	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
but	NULL
not	NULL
on	NULL
protein	NULL
synthesis	NULL
or	NULL
increase	NULL
in	NULL
intracellular	NULL
calcium	NULL
or	NULL
CsA	NULL
.	NULL

E6G-	NULL
1	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
cyclosporine	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
,	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
)	NULL
,	NULL
verapamil	NULL
(	NULL
ver	NULL
)	NULL
,	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
)	NULL
,	NULL
or	NULL
H7	NULL
and	NULL
stimulated	NULL
with	NULL
gp160	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Electromobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

activation	NULL
.	NULL

A	NULL
more	NULL
specific	NULL
inhibitor	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
activity	NULL
,	NULL
calphostin	NULL
(	NULL
33	NULL
)	NULL
also	NULL
inhibited	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
binding	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Cyclosporine	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
,	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
)	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
activation	NULL
of	NULL
AP-1	NULL
,	NULL
as	NULL
did	NULL
the	NULL
calcium	NULL
channel	NULL
blocker	NULL
,	NULL
verapamil	NULL
(	NULL
ver	NULL
)	NULL
.	NULL

These	NULL
studies	NULL
indicate	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
were	NULL
involved	NULL
in	NULL
the	NULL
19367	NULL
TaBLE	NULL
I	NULL
Gp120	NULL
inhibits	NULL
anti-CD3-induced	NULL
IL-2	NULL
secretion	NULL
CD4+	NULL
T	NULL
cells	NULL
(	NULL
E6-1	NULL
)	NULL
,	NULL
CD4-	NULL
T	NULL
cells	NULL
(	NULL
JN	NULL
)	NULL
or	NULL
purified	NULL
peripheral	NULL
blood	NULL
CD4+	NULL
T	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
gp160	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
(	NULL
Leu3a	NULL
)	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
and	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
(	NULL
mAb	NULL
454	NULL
)	NULL
plus	NULL
PMA	NULL
for	NULL
24	NULL
h.	NULL
Culture	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
IL-2	NULL
secretion	NULL
by	NULL
commercial	NULL
ELISA	NULL
kits	NULL
.	NULL

Numbers	NULL
denote	NULL
mean	NULL
and	NULL
standard	NULL
deviation	NULL
of	NULL
triplicates	NULL
and	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
separate	NULL
experiments	NULL
.	NULL

Unstimulated	NULL
E6-1	NULL
cells	NULL
,	NULL
JN	NULL
cells	NULL
,	NULL
and	NULL
purified	NULL
T	NULL
cells	NULL
secreted	NULL
79	NULL
,	NULL
52	NULL
,	NULL
and	NULL
127	NULL
pg/ml	NULL
IL-2	NULL
,	NULL
respectively	NULL
.	NULL

IL-2	NULL
(	NULL
%	NULL
inhibition	NULL
)	NULL
Pretreatment	NULL
=-CD4+	NULL
T	NULL
cells	NULL
CD4+	NULL
E6-1	NULL
cells	NULL
CD4-	NULL
JN	NULL
cells	NULL
pg/ml	NULL
None	NULL
1862	NULL
+	NULL
30	NULL
475	NULL
+	NULL
36	NULL
1081	NULL
+	NULL
67	NULL
gp160	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
786	NULL
+	NULL
49	NULL
(	NULL
58	NULL
)	NULL
-	NULL
407	NULL
+	NULL
20	NULL
(	NULL
14	NULL
)	NULL
362	NULL
+	NULL
16	NULL
(	NULL
67	NULL
)	NULL
gp160	NULL
(	NULL
0.1	NULL
ug/ml	NULL
)	NULL
1063	NULL
+	NULL
38	NULL
(	NULL
43	NULL
)	NULL
415	NULL
+	NULL
62	NULL
(	NULL
13	NULL
)	NULL
758	NULL
+	NULL
29	NULL
(	NULL
30	NULL
)	NULL
gp160	NULL
(	NULL
0.01	NULL
ug/ml	NULL
)	NULL
1480	NULL
+	NULL
60	NULL
(	NULL
20	NULL
)	NULL
_	NULL
420	NULL
+	NULL
37	NULL
(	NULL
12	NULL
)	NULL
906	NULL
+	NULL
11	NULL
(	NULL
16	NULL
)	NULL
Leusa	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
897	NULL
+	NULL
56	NULL
(	NULL
51	NULL
)	NULL
-	NULL
438	NULL
+	NULL
46	NULL
(	NULL
8	NULL
)	NULL
560	NULL
+	NULL
47	NULL
(	NULL
48	NULL
)	NULL
Leusa	NULL
(	NULL
0.1	NULL
ug/ml	NULL
)	NULL
1306	NULL
+	NULL
118	NULL
(	NULL
30	NULL
)	NULL
408	NULL
+	NULL
50	NULL
(	NULL
14	NULL
)	NULL
807	NULL
+	NULL
64	NULL
(	NULL
25	NULL
)	NULL
Leusa	NULL
(	NULL
0.01	NULL
ug/ml	NULL
)	NULL
1742	NULL
+	NULL
74	NULL
(	NULL
6	NULL
)	NULL
483	NULL
+	NULL
107	NULL
(	NULL
+2	NULL
)	NULL
1005	NULL
+	NULL
38	NULL
(	NULL
7	NULL
)	NULL
mechanism	NULL
of	NULL
the	NULL
gp160-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
binding	NULL
.	NULL

gp120	NULL
Inhibits	NULL
IL-2	NULL
Secretion	NULL
by	NULL
CD4+	NULL
T	NULL
Cells-E6-1	NULL
cells	NULL
or	NULL
purified	NULL
peripheral	NULL
blood	NULL
CD4+	NULL
T	NULL
cells	NULL
were	NULL
pretreated	NULL
with	NULL
1	NULL
ug/ml	NULL
gp120	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
(	NULL
which	NULL
induced	NULL
AP-1	NULL
binding	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
plus	NULL
PMA	NULL
for	NULL
an	NULL
additional	NULL
24	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
and	NULL
culture	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
IL-2	NULL
secretion	NULL
.	NULL

Table	NULL
I	NULL
shows	NULL
that	NULL
gp120-	NULL
or	NULL
anti-CD4	NULL
mAb-treated	NULL
E6-1	NULL
cells	NULL
and	NULL
CD4+	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
were	NULL
markedly	NULL
inhibited	NULL
in	NULL
their	NULL
ability	NULL
to	NULL
secrete	NULL
IL-2	NULL
in	NULL
response	NULL
to	NULL
anti-CD3	NULL
mAb	NULL
.	NULL

Pretreatment	NULL
of	NULL
the	NULL
CD4	NULL
negative	NULL
T	NULL
cells	NULL
(	NULL
JN	NULL
)	NULL
cells	NULL
with	NULL
gp120	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
,	NULL
however	NULL
,	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
anti-CD3	NULL
mAb	NULL
plus	NULL
PMA-induced	NULL
IL-2	NULL
secretion	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
demonstrated	NULL
that	NULL
the	NULL
addition	NULL
of	NULL
gp160	NULL
to	NULL
CD4+	NULL
T	NULL
cells	NULL
induces	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
AP-1	NULL
by	NULL
signals	NULL
transduced	NULL
directly	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
.	NULL

Signals	NULL
transduced	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
on	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
regulating	NULL
T	NULL
cell	NULL
functional	NULL
responses	NULL
mediated	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Earlier	NULL
studies	NULL
had	NULL
implicated	NULL
that	NULL
the	NULL
binding	NULL
(	NULL
adhesion	NULL
)	NULL
of	NULL
the	NULL
CD4	NULL
molecule	NULL
with	NULL
its	NULL
natural	NULL
ligand	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
molecule	NULL
,	NULL
participated	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
stabilizing	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
-MHC	NULL
interactions	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
inhibition	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
by	NULL
anti-CD4	NULL
mAbs	NULL
in	NULL
MHC	NULL
class	NULL
II	NULL
independent	NULL
systems	NULL
suggested	NULL
that	NULL
inhibitory	NULL
signals	NULL
were	NULL
transduced	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
(	NULL
35	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
recent	NULL
experiments	NULL
have	NULL
indicated	NULL
that	NULL
positive	NULL
signals	NULL
may	NULL
be	NULL
induced	NULL
via	NULL
the	NULL
CD4	NULL
molecule	NULL
,	NULL
either	NULL
by	NULL
anti-CD4	NULL
mAbs	NULL
(	NULL
36	NULL
)	NULL
or	NULL
by	NULL
HIV	NULL
envelope	NULL
glycoproteins	NULL
,	NULL
gp160/gp120	NULL
(	NULL
2-5	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
CD4-induced	NULL
signals	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
synergize	NULL
with	NULL
anti-CD3	NULL
or	NULL
anti-TCR	NULL
mAb	NULL
(	NULL
37	NULL
)	NULL
the	NULL
aberrant	NULL
persistent	NULL
activation	NULL
through	NULL
this	NULL
molecule	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
disease	NULL
,	NULL
e.g	NULL
.	NULL

in	NULL
HIV	NULL
infection	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Cellular	NULL
activation	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
HIV	NULL
infection	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Virus	NULL
internalization	NULL
,	NULL
syncitium	NULL
formation	NULL
,	NULL
and	NULL
proviral	NULL
replication	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
require	NULL
cellular	NULL
activation	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Several	NULL
investigators	NULL
have	NULL
demonstrated	NULL
that	NULL
binding	NULL
of	NULL
gp160/gp120	NULL
to	NULL
CD4	NULL
molecules	NULL
on	NULL
the	NULL
cell	NULL
surface	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
biochemical	NULL
signals	NULL
(	NULL
2-5	NULL
)	NULL
.	NULL

We	NULL
have	NULL
demonstrated	NULL
that	NULL
binding	NULL
of	NULL
gp160	NULL
,	NULL
(	NULL
at	NULL
concentrations	NULL
found	NULL
in	NULL
vivo	NULL
,	NULL
(	NULL
32	NULL
)	NULL
)	NULL
to	NULL
CD4	NULL
molecules	NULL
on	NULL
T	NULL
cells	NULL
can	NULL
induce	NULL
biological	NULL
events	NULL
,	NULL
e.g	NULL
.	NULL

up-regulation	NULL
of	NULL
CD40	NULL
ligand	NULL
(	NULL
15	NULL
)	NULL
,	NULL
secretion	NULL
of	NULL
IL-6	NULL
,	NULL
IL-3	NULL
,	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
interferon	NULL
y	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
,	NULL
and	NULL
up-regulation	NULL
of	NULL
Fas	NULL
antigen	NULL
(	NULL
17	NULL
)	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
observations	NULL
unequivocally	NULL
dem	NULL
19368	NULL
onstrate	NULL
that	NULL
gp160	NULL
can	NULL
transduce	NULL
signals	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
in	NULL
T	NULL
cells	NULL
culminating	NULL
into	NULL
biological	NULL
events	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
gp160	NULL
can	NULL
induce	NULL
activation	NULL
of	NULL
AP-1	NULL
in	NULL
CD4+	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
Fos/Jun	NULL
family	NULL
of	NULL
proteins	NULL
in	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
complex	NULL
was	NULL
confirmed	NULL
by	NULL
abrogation	NULL
of	NULL
AP-1	NULL
binding	NULL
in	NULL
immunoprecipitation	NULL
experiments	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
needed	NULL
to	NULL
determine	NULL
the	NULL
involvement	NULL
and	NULL
functional	NULL
role	NULL
of	NULL
individual	NULL
Fos/Jun	NULL
components	NULL
in	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
complex	NULL
.	NULL

The	NULL
stimulatory	NULL
effects	NULL
of	NULL
gp160	NULL
are	NULL
mediated	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
,	NULL
since	NULL
pretreatment	NULL
of	NULL
gp160	NULL
with	NULL
soluble	NULL
CD4-	NULL
IgG	NULL
abrogates	NULL
its	NULL
activity	NULL
.	NULL

Furthermore	NULL
,	NULL
cell	NULL
lines	NULL
expressing	NULL
the	NULL
CD4	NULL
molecule	NULL
(	NULL
H9	NULL
,	NULL
Molt4	NULL
)	NULL
,	NULL
but	NULL
not	NULL
CD4	NULL
negative	NULL
cell	NULL
line	NULL
(	NULL
JN	NULL
)	NULL
,	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
gp160	NULL
to	NULL
activate	NULL
AP-1	NULL
.	NULL

gp160	NULL
can	NULL
also	NULL
stimulate	NULL
peripheral	NULL
blood	NULL
CD4	NULL
positive	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
CD8	NULL
positive	NULL
T	NULL
cells	NULL
to	NULL
activate	NULL
AP-1	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
stimulatory	NULL
effects	NULL
of	NULL
gp160	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
anti-CD4	NULL
mAb	NULL
.	NULL

These	NULL
results	NULL
clearly	NULL
demonstrate	NULL
AP-1	NULL
activation	NULL
by	NULL
direct	NULL
stimulation	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
.	NULL

Post-translational	NULL
modifications	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
involve	NULL
activation	NULL
of	NULL
pre-existing	NULL
Fos/Jun	NULL
by	NULL
intracellular	NULL
kinases	NULL
and	NULL
phosphatases	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
,	NULL
CHX	NULL
failed	NULL
to	NULL
abrogate	NULL
(	NULL
and	NULL
in	NULL
fact	NULL
aug-ments	NULL
)	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
binding	NULL
at	NULL
4	NULL
h	NULL
suggests	NULL
that	NULL
post-translational	NULL
modification	NULL
of	NULL
preexisting	NULL
Fos	NULL
and/or	NULL
Jun	NULL
induces	NULL
AP-1	NULL
binding	NULL
at	NULL
4	NULL
h.	NULL
Tyrosine	NULL
phosphorylation	NULL
inhibitor	NULL
,	NULL
herbimycin	NULL
A	NULL
,	NULL
abrogated	NULL
the	NULL
gp160-induced	NULL
AP-1	NULL
binding	NULL
.	NULL

In	NULL
resting	NULL
cells	NULL
,	NULL
the	NULL
pre-existing	NULL
Jun	NULL
is	NULL
phosphorylated	NULL
on	NULL
three	NULL
sites	NULL
at	NULL
the	NULL
C-terminal	NULL
domain	NULL
next	NULL
to	NULL
its	NULL
DNA	NULL
binding	NULL
domains	NULL
(	NULL
21	NULL
)	NULL
;	NULL
phosphorylated	NULL
states	NULL
of	NULL
these	NULL
sites	NULL
inhibits	NULL
DNA	NULL
binding	NULL
(	NULL
41	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
Jun	NULL
requires	NULL
dephosphorylation	NULL
of	NULL
these	NULL
sites	NULL
,	NULL
possibly	NULL
by	NULL
a	NULL
protein	NULL
kinase	NULL
C-activated	NULL
phosphatase	NULL
(	NULL
42	NULL
)	NULL
.	NULL

Calcineurin	NULL
,	NULL
the	NULL
phosphatase	NULL
that	NULL
modulates	NULL
NFAT	NULL
activity	NULL
(	NULL
43	NULL
)	NULL
,	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
c-Jun	NULL
dephosphorylation	NULL
,	NULL
since	NULL
AP-1	NULL
binding	NULL
is	NULL
unaffected	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
cyclosporine	NULL
A	NULL
.	NULL

While	NULL
intracellular	NULL
calcium	NULL
channel	NULL
blocker	NULL
,	NULL
verapamil	NULL
,	NULL
failed	NULL
to	NULL
block	NULL
AP-1	NULL
binding	NULL
,	NULL
the	NULL
requirement	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
for	NULL
the	NULL
gp160-mediated	NULL
AP-1	NULL
binding	NULL
was	NULL
demonstrated	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
inhibitors	NULL
,	NULL
H7	NULL
and	NULL
calphostin	NULL
.	NULL

Understanding	NULL
the	NULL
precise	NULL
nature	NULL
of	NULL
the	NULL
post-tran-scriptional	NULL
modification	NULL
involving	NULL
activation	NULL
of	NULL
the	NULL
Ha-Ras	NULL
on-coprotein	NULL
(	NULL
44	NULL
,	NULL
45	NULL
)	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
pathway	NULL
(	NULL
46	NULL
)	NULL
,	NULL
or	NULL
the	NULL
newly	NULL
described	NULL
JNK	NULL
and	NULL
SAPK	NULL
pathways	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
may	NULL
give	NULL
an	NULL
insight	NULL
into	NULL
the	NULL
regulatory	NULL
role	NULL
of	NULL
CD4-mediated	NULL
signals	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

AP-1	NULL
has	NULL
been	NULL
demonstrated	NULL
to	NULL
be	NULL
target	NULL
for	NULL
T	NULL
cell	NULL
clonal	NULL
anergy	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
down-modulation	NULL
of	NULL
AP-1	NULL
binding	NULL
and	NULL
transactivation	NULL
in	NULL
anergized	NULL
T	NULL
cell	NULL
clones	NULL
(	NULL
49	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
pretreatment	NULL
of	NULL
CD4+	NULL
T	NULL
cells	NULL
with	NULL
envelope	NULL
proteins	NULL
of	NULL
HIV-1	NULL
can	NULL
induce	NULL
unresponsiveness	NULL
of	NULL
T	NULL
cells	NULL
upon	NULL
stimulation	NULL
through	NULL
TCRCD3	NULL
complex	NULL
(	NULL
23-26	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
stimulatory	NULL
effect	NULL
of	NULL
gp160	NULL
on	NULL
AP-1	NULL
binding	NULL
,	NULL
involving	NULL
the	NULL
repressive	NULL
members	NULL
of	NULL
the	NULL
Jun	NULL
family	NULL
,	NULL
i.e	NULL
.	NULL

JunB	NULL
(	NULL
50	NULL
,	NULL
51	NULL
)	NULL
,	NULL
which	NULL
may	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
.	NULL

Our	NULL
previous	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
pretreatment	NULL
of	NULL
T	NULL
cell	NULL
clones	NULL
with	NULL
envelope	NULL
glycoproteins	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
inhibited	NULL
IL-2	NULL
secretion	NULL
at	NULL
the	NULL
tran-scriptional	NULL
level	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
pretreatment	NULL
of	NULL
the	NULL
CD4+	NULL
T	NULL
cells	NULL
with	NULL
gp160	NULL
or	NULL
anti-CD4	NULL
mAb	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
(	NULL
which	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
AP-1	NULL
binding	NULL
)	NULL
inhibits	NULL
anti-CD3	NULL
plus	NULL
PMA-induced	NULL
IL-2	NULL
secretion	NULL
.	NULL

Since	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
secretion	NULL
by	NULL
gp120	NULL
in	NULL
these	NULL
experiments	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
antigen	NULL
presenting	NULL
cells	NULL
,	NULL
it	NULL
can	NULL
be	NULL
hypothesized	NULL
that	NULL
signals	NULL
mediated	NULL
through	NULL
the	NULL
CD4	NULL
molecule	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
results	NULL
in	NULL
activation	NULL
of	NULL
AP-1	NULL
,	NULL
may	NULL
interfere	NULL
with	NULL
signal	NULL
transduction	NULL
through	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
.	NULL

HIV-1	NULL
Glycoproteins	NULL
Induce	NULL
Activation	NULL
of	NULL
AP-1	NULL
in	NULL
CD4+	NULL
T	NULL
Cells	NULL
Given	NULL
that	NULL
the	NULL
promoters	NULL
of	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
IL-6	NULL
,	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
,	NULL
TCR	NULL
$	NULL
,	NULL
and	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
contain	NULL
AP-1	NULL
binding	NULL
sites	NULL
(	NULL
18	NULL
,	NULL
52-56	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
gp160-induced	NULL
activation	NULL
of	NULL
AP-1	NULL
in	NULL
T	NULL
cells	NULL
can	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
molecules	NULL
.	NULL

Since	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
have	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
the	NULL
mechanism	NULL
of	NULL
apoptosis	NULL
(	NULL
57	NULL
,	NULL
58	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
gp160-induced	NULL
AP-1	NULL
activation	NULL
may	NULL
play	NULL
a	NULL
significant	NULL
role	NULL
in	NULL
apoptosis	NULL
mechanisms	NULL
in	NULL
HIV	NULL
infec-tion	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
soluble	NULL
envelope	NULL
glycoproteins	NULL
of	NULL
HIV-1	NULL
,	NULL
gp160	NULL
,	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
CD4	NULL
molecule	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
may	NULL
transduce	NULL
signals	NULL
that	NULL
result	NULL
in	NULL
aberrant	NULL
activation	NULL
of	NULL
AP-1	NULL
.	NULL

These	NULL
effects	NULL
by	NULL
gp160	NULL
,	NULL
or	NULL
by	NULL
HIV	NULL
itself	NULL
in	NULL
vivo	NULL
,	NULL
may	NULL
contribute	NULL
to	NULL
biological	NULL
events	NULL
,	NULL
e.g	NULL
.	NULL

enhanced	NULL
HIV	NULL
replication	NULL
,	NULL
hypergammaglobulinemia	NULL
,	NULL
increased	NULL
cytokine	NULL
secretion	NULL
,	NULL
hypercellularity	NULL
in	NULL
bone	NULL
marrow	NULL
,	NULL
apoptosis	NULL
,	NULL
and	NULL
induction	NULL
of	NULL
T	NULL
cell	NULL
unresponsiveness	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Capon	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Ward	NULL
,	NULL
R.	NULL
H.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

9	NULL
,	NULL
649-678	NULL
2	NULL
.	NULL

Kornfeld	NULL
,	NULL
H.	NULL
,	NULL
Cruickshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Pyle	NULL
,	NULL
S.	NULL
,	NULL
Berman	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
835	NULL
,	NULL
445-454	NULL
3	NULL
.	NULL

Soula	NULL
,	NULL
M.	NULL
,	NULL
Fagard	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Fischer	NULL
,	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

4	NULL
,	NULL
295-299	NULL
4	NULL
.	NULL

Hivroz	NULL
,	NULL
C.	NULL
,	NULL
Mazerolles	NULL
,	NULL
F.	NULL
,	NULL
Soula	NULL
,	NULL
M.	NULL
,	NULL
Fagard	NULL
,	NULL
R.	NULL
,	NULL
Graton	NULL
,	NULL
S.	NULL
,	NULL
Meloche	NULL
,	NULL
S.	NULL
,	NULL
Sekaly	NULL
,	NULL
R.-P.	NULL
,	NULL
and	NULL
Fischer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
600-607	NULL
5	NULL
.	NULL

Cruickshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Center	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
Pyle	NULL
,	NULL
S.	NULL
W.	NULL
,	NULL
and	NULL
Kornfeld	NULL
,	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Biomed	NULL
.	NULL

Pharmacother	NULL
.	NULL

44	NULL
,	NULL
5-11	NULL
6	NULL
.	NULL

Horak	NULL
,	NULL
I.	NULL
D.	NULL
,	NULL
Popovic	NULL
,	NULL
M.	NULL
,	NULL
Horak	NULL
,	NULL
E.	NULL
,	NULL
Lucas	NULL
,	NULL
P.	NULL
,	NULL
Gress	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
and	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
848	NULL
,	NULL
557-560	NULL
7	NULL
.	NULL

Orloff	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Kennedy	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Dawson	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
McDougal	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
7	NULL
,	NULL
587-598	NULL
8	NULL
.	NULL

Janeway	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Semin	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
153-160	NULL
9	NULL
.	NULL

Glainchenhaus	NULL
,	NULL
N.	NULL
,	NULL
Shastri	NULL
,	NULL
N.	NULL
,	NULL
Littman	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
and	NULL
Turner	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
511-520	NULL
10	NULL
.	NULL

Zamoyska	NULL
,	NULL
R.	NULL
,	NULL
Derham	NULL
,	NULL
P.	NULL
,	NULL
Gorman	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
von	NULL
Hoegden	NULL
,	NULL
P.	NULL
,	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Veillette	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Parnes	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
342	NULL
,	NULL
278-280	NULL
11	NULL
.	NULL

Veillette	NULL
,	NULL
A.	NULL
,	NULL
Abraham	NULL
,	NULL
N.	NULL
,	NULL
Caron	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Davidson	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
Semun	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
148-152	NULL
12	NULL
.	NULL

Telfer	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Rudd	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
Science	NULL
254	NULL
,	NULL
439-441	NULL
13	NULL
.	NULL

Prasad	NULL
,	NULL
K.	NULL
V.	NULL
S.	NULL
,	NULL
Keppler	NULL
,	NULL
R.	NULL
,	NULL
Janssen	NULL
,	NULL
O.	NULL
,	NULL
Repke	NULL
,	NULL
H.	NULL
,	NULL
Duke-Cohan	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
and	NULL
Rudd	NULL
,	NULL
C.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
7708-7717	NULL
14	NULL
.	NULL

Chirmule	NULL
,	NULL
N.	NULL
,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

203	NULL
,	NULL
498-505	NULL
15	NULL
.	NULL

Chirmule	NULL
,	NULL
N.	NULL
,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
Lederman	NULL
,	NULL
S.	NULL
,	NULL
Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
Yagura	NULL
,	NULL
H.	NULL
,	NULL
Yellin	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Chess	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
2478-2486	NULL
16	NULL
.	NULL

Than	NULL
,	NULL
S.	NULL
,	NULL
Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
Pahwa	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Blood	NULL
84	NULL
,	NULL
184-189	NULL
17	NULL
.	NULL

Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
McCloskey	NULL
,	NULL
T.	NULL
,	NULL
Than	NULL
,	NULL
S.	NULL
,	NULL
Hu	NULL
,	NULL
R.	NULL
,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Blood	NULL
84	NULL
,	NULL
2622-2631	NULL
18	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1240-1250	NULL
19	NULL
.	NULL

Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
55	NULL
,	NULL
395-397	NULL
20	NULL
.	NULL

Lee	NULL
,	NULL
W.	NULL
,	NULL
Mitchell	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Tijan	NULL
,	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
741-752	NULL
21	NULL
.	NULL

Angel	NULL
.	NULL

,	NULL
P.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
120-157	NULL
22	NULL
.	NULL

Fauci	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
289	NULL
,	NULL
617-622	NULL
23	NULL
.	NULL

Habeshaw	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Dalgleish	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Bountiff	NULL
,	NULL
L.	NULL
,	NULL
Newell	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Wilks	NULL
,	NULL
D.	NULL
,	NULL
Walker	NULL
,	NULL
L.	NULL
C.	NULL
,	NULL
and	NULL
Manca	NULL
,	NULL
F.	NULL
(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
11	NULL
,	NULL
418-425	NULL
24	NULL
.	NULL

Chirmule	NULL
,	NULL
N.	NULL
,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
Slade	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Blood	NULL
75	NULL
,	NULL
152-159	NULL
25	NULL
.	NULL

Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
Chirmule	NULL
,	NULL
N.	NULL
,	NULL
Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
Hall	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Good	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
2379-2383	NULL
26	NULL
.	NULL

Oyaizu	NULL
,	NULL
N.	NULL
,	NULL
Chirmule	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Pahwa	NULL
,	NULL
S.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

89	NULL
,	NULL
1807-1816	NULL
27	NULL
.	NULL

Goldman	NULL
,	NULL
F.	NULL
,	NULL
Jensen	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Heasley	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Cambier	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

153	NULL
,	NULL
2905-2917	NULL
28	NULL
.	NULL

Kalyanaraman	NULL
,	NULL
V.	NULL
S.	NULL
,	NULL
Veronese	NULL
,	NULL
F.	NULL
,	NULL
Rahman	NULL
,	NULL
R.	NULL
,	NULL
Lusso	NULL
,	NULL
P.	NULL
,	NULL
Devico	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Copeland	NULL
,	NULL
T.	NULL
,	NULL
Oroszlan	NULL
,	NULL
S.	NULL
,	NULL
Gallo	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Sarngadharan	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
6	NULL
,	NULL
371-380	NULL
29	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Skocil	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

183	NULL
,	NULL
123-128	NULL
30	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Leibowitz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
and	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1983	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11	NULL
,	NULL
1475-1489	NULL
31	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
Imagawa	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
Imbra	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Jonat	NULL
,	NULL
C.	NULL
,	NULL
Herrlich	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
729-739	NULL
32	NULL
.	NULL

Oh	NULL
,	NULL
S.-Y	NULL
.	NULL

,	NULL
Cruickshank	NULL
,	NULL
W.	NULL
W.	NULL
,	NULL
Raina	NULL
,	NULL
J.	NULL
,	NULL
Blanchard	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Adler	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Walker	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Kornfeld	NULL
,	NULL
H.	NULL
(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

AIDS	NULL
.	NULL

5	NULL
,	NULL
251-256	NULL
33	NULL
.	NULL

Gublins	NULL
,	NULL
H.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Baier	NULL
,	NULL
G.	NULL
,	NULL
Telford	NULL
,	NULL
D.	NULL
,	NULL
Langlet	NULL
,	NULL
C.	NULL
,	NULL
Baier-Bitterlich	NULL
,	NULL
G.	NULL
,	NULL
Berrard-Bonnefoy	NULL
,	NULL
N.	NULL
,	NULL
Burn	NULL
,	NULL
P.	NULL
,	NULL
Wittinghofer	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
4749-4758	NULL
34	NULL
.	NULL

Biddison	NULL
,	NULL
W.	NULL
E.	NULL
,	NULL
Rao	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Talle	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Goldstein	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Shaw	NULL
,	NULL
S.	NULL
(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

181	NULL
,	NULL
152-187	NULL
35	NULL
.	NULL

Bank	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Chess	NULL
,	NULL
L.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Exp	NULL
Med	NULL
.	NULL

162	NULL
,	NULL
1294-1303	NULL
36	NULL
.	NULL

Carrel	NULL
,	NULL
S.	NULL
,	NULL
Salvi	NULL
,	NULL
S.	NULL
,	NULL
Gallay	NULL
,	NULL
P.	NULL
,	NULL
Rapin	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Sekaly	NULL
,	NULL
R.	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Res	NULL
.	NULL

Immunol	NULL
.	NULL

142	NULL
,	NULL
97-108	NULL
37	NULL
.	NULL

Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Deans	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Aruffo	NULL
,	NULL
A.	NULL
,	NULL
Grsomarie	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Kanner	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Schieven	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
384-8343	NULL
38	NULL
.	NULL

Ascher	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
Sheppard	NULL
,	NULL
H.	NULL
W.	NULL
(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

AIDS	NULL
8	NULL
,	NULL
177-191	NULL
39	NULL
.	NULL

Gowda	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
S.	NULL
,	NULL
Mohagheghpour	NULL
,	NULL
N.	NULL
,	NULL
Benike	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
and	NULL
Engleman	NULL
,	NULL
E.	NULL
G.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
773-780	NULL
40	NULL
.	NULL

McDougal	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
Mawle	NULL
,	NULL
A.	NULL
,	NULL
Cort	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Nicholson	NULL
,	NULL
J.	NULL
K.	NULL
A.	NULL
,	NULL
Cross	NULL
,	NULL
G.	NULL
D.	NULL
,	NULL
Scheppler-Campbell	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hicks	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Sligh	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

185	NULL
,	NULL
41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

HIV-1	NULL
Glycoproteins	NULL
Induce	NULL
Activation	NULL
of	NULL
AP-1	NULL
in	NULL
CD4+	NULL
T	NULL
Cells	NULL
3151-3162	NULL
Lin	NULL
,	NULL
A.	NULL
,	NULL
Frost	NULL
,	NULL
J.	NULL
,	NULL
Deng	NULL
,	NULL
T.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Alawi	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Kikkawa	NULL
,	NULL
U.	NULL
,	NULL
Hunter	NULL
,	NULL
T.	NULL
,	NULL
Brenner	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
777-789	NULL
Boyle	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Defize	NULL
,	NULL
L.	NULL
H.	NULL
K.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hunter	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
64	NULL
,	NULL
573-584	NULL
Flannagan	NULL
,	NULL
W.	NULL
F.	NULL
,	NULL
Corthesy	NULL
,	NULL
B.	NULL
,	NULL
Bram	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
852	NULL
,	NULL
803-807	NULL
Deng	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
371	NULL
,	NULL
171-175	NULL
Coffer	NULL
,	NULL
P.	NULL
,	NULL
deJonge	NULL
,	NULL
M.	NULL
,	NULL
Mettouchi	NULL
,	NULL
A.	NULL
,	NULL
Binetruy	NULL
,	NULL
B.	NULL
,	NULL
Ghysdael	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Kruijer	NULL
,	NULL
W.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
911-921	NULL
Pulverer	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
Kyriaka	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Avruch	NULL
,	NULL
J.	NULL
,	NULL
Nikolakaki	NULL
,	NULL
E.	NULL
,	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
858	NULL
,	NULL
670-672	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
A.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Minden	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
2135-2148	NULL
Kriakis	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Banerjee	NULL
,	NULL
P.	NULL
,	NULL
Nikolakaki	NULL
,	NULL
E.	NULL
,	NULL
Dai	NULL
,	NULL
T.	NULL
,	NULL
Rubie	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Ahmad	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Avruch	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Woodgett	NULL
,	NULL
J.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
369	NULL
,	NULL
156-160	NULL
Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
Beverley	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.-C.	NULL
,	NULL
Bronson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

19369	NULL
Leonardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1134-1138	NULL
Deng	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
T.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
&	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
479-490	NULL
Hsu	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Cressman	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
and	NULL
Taub	NULL
,	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

58	NULL
,	NULL
3789-3794	NULL
Messier	NULL
,	NULL
H.	NULL
,	NULL
Ratanavongsiri	NULL
,	NULL
J.	NULL
,	NULL
Fuller	NULL
,	NULL
T.	NULL
,	NULL
Mangal	NULL
,	NULL
S.	NULL
,	NULL
Kilgannon	NULL
,	NULL
P.	NULL
,	NULL
Fotedar	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Fotedar	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

149	NULL
,	NULL
1980-1986	NULL
Newell	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Deisseroth	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
Lopez-Berestein	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

56	NULL
,	NULL
27-35	NULL
Park	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Kaushansky	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Levitt	NULL
,	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268	NULL
,	NULL
6299-6308	NULL
Adunyah	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Unlap	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Wagner	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Kraft	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
5670-5675	NULL
Vanlint	NULL
,	NULL
C.	NULL
,	NULL
Burny	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Verdin	NULL
,	NULL
E.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

65	NULL
,	NULL
7066-7072	NULL
Smeye	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Vendrell	NULL
,	NULL
M.	NULL
,	NULL
Hayward	NULL
,	NULL
M.	NULL
,	NULL
Baker	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Miao	NULL
,	NULL
G.	NULL
G.	NULL
,	NULL
Schilling	NULL
,	NULL
K.	NULL
,	NULL
Robertson	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Morgan	NULL
,	NULL
J.	NULL
I	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Nature	NULL
363	NULL
,	NULL
166-169	NULL
Lavin	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
and	NULL
Goldstone	NULL
,	NULL
S.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
2305-2311	NULL

